Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.

You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings

Accept

;

Explore our recent stories to see what drives us

15 May 2020

Grünenthal’s 2019/20 annual report shares insights into our record-breaking year

The 2019/20 Grünenthal Report
Grünenthal achieved the best ever financial performance in 2019 with EBITDA growth exceeding 60 percent – and took some major entrepreneurial and strategic steps forward. Stories from the company’s record-breaking year are available to read in our annual report.

“2019 was a successful year for us, and we are excited to continue our company’s long track record of changing patients’ lives for the better.”

Gabriel Baertschi,

Chief Executive Officer

The 2019/20 Grünenthal Report looks back on a record year in terms of financial performance, and shares insights into some of the key projects that made this success possible. We have realigned our R&D strategy and implemented a new R&D model that aims to strengthen its position as an innovation-driven company. As part of this approach, Grünenthal is focusing on four core indications with high unmet medical needs: peripheral neuropathic pain, chronic postoperative pain, chronic low back pain, and osteoarthritis. On top of this, Grünenthal opened its first Innovation Hub in Boston in 2019.
The report also includes details about Grünenthal’s first ever cell therapy project, a strategic partnership with Mesoblast that is exploring an innovative investigational treatment for chronic low back pain caused by degenerative disc disease. The successful integration of Nexium™ and Vimovo™, is another highlight. These two pain-related brands were acquired in 2018 as part of the biggest investment in Grünenthal’s history, and both performed above target levels in 2019.

Grünenthal also submitted a supplemental new drug application to expand the Qutenza™ US label in 2019. If successful, it will enable Qutenza™ to be used to treat patients with painful diabetic peripheral neuropathy, opening up a significant opportunity to meet the medical needs of the large number of patients in the US who have been diagnosed with this condition. And the company also established an innovative start-up called Fern Health, which provides a digital concierge service for patients with musculoskeletal pain in the US.

Read all about it in the digital edition of our Grünenthal Report 2019/20 which is now online or download the report as a pdf.

Share This Story: